Since when do analysts value experimental biotechs based on financials, earnings etc. What a crock! this article has no merit and is only done to drive down the price. Inovio and other biotechs like it are valued based on new drug candidates and drugs in clinical trials not earnings. Hatchet job.
Scott Olson, the Street author, graduated from the University of Massachusetts in 1999 with a bachelors in English prior to moving to California and working with the founders of Trade Ideas at FutureTrade Tech. I heard he shares a cube with AF @ The Street.
I just called the 1866-321-8726 number and cancelled all emails and advertizements that were polluting my computer. When I was asked what was the reason? I said that in my opinion, based on all the one sided articles, I believed Cramer and all the clowns were on their own mission and not the interest of the individual Investor. The man was gracious and apologized.